A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Novo Nordisk's (NYSE: NVO ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month ...

Novo Nordisk has become a global sensation with its popular weight loss drugs like Ozempic and Wegovy. On Wednesday, the Danish multinational pharmaceutical company announced that it would begin ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 12 trades. If we consider the specifics of ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).

Novo Nordisk, manufacturer of the weight loss jab Wegovy, has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations (Alamy/PA ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...